$MRK

Amgen and Merck offer 3% dividend yields while successfully managing patent cliffs through diversified pipelines and new product approvals.

Biotech firm Immutrin appoints Dr. Robert Blaustein as Chief Medical Officer and establishes US subsidiary to advance amyloidosis antibody therapy toward clinical trials.

InVitria showcases Exbumin® and Optibumin® 25 recombinant albumins at IPEC Biologics Summit, highlighting use in approved medicines including Merck's ERVEBO®.

Merck posts Q1 loss on Cidara acquisition charge but beats revenue expectations with 5% sales growth, raises 2026 guidance.

Global bulk filtration market expands through 2031 as environmental regulations, IoT integration, and smart technologies drive adoption across pharmaceuticals, water treatment, and industrial sectors.

Global antibiotic resistance market to grow from $9.78B (2026) to $12.72B (2031) at 5.4% CAGR, driven by rising drug-resistant infections and antimicrobial innovation.

Sun Pharma agrees to acquire Organon for $14/share in all-cash deal, sending shares up 16.87% as women's health firm finds exit after struggling 2021 Merck spinoff.

AI technologies achieving 85-95% accuracy in biomarker identification are reshaping lung cancer drug discovery, with $3B in recent funding backing innovation by major pharma firms.

PTCL market valued at USD 800 million in 2025 to grow 7% annually through 2036, driven by emerging therapies and rising disease incidence. U.S. represents 68% of market.

Biotech M&A surges as $300B patent cliff looms by 2030. Three gene-editing firms positioned as acquisition targets offer varying risk profiles.

Mental health clinical trials market projected to grow 51% from $3.23B (2025) to $4.89B (2030) at 8.6% CAGR, driven by digital innovation and Asia-Pacific expansion.

Inhibrx is fielding takeover interest from major pharma for cancer drug INBRX-106 in potential $9B spin-off; stock surges 39.86%.

Polycythemia vera market expected to expand 8.9% CAGR through 2036 from $2B base as nine pharma companies advance novel therapies, with rusfertide entering first.

Global vulvar cancer market expected to expand through 2035, driven by aging populations and HPV prevalence. Merck, Bristol Myers Squibb, and AstraZeneca lead innovation in immunotherapies despite reimbursement headwinds.

Merck shares dropped 4% after Phase 3 cancer trial failure, but FDA approval of HIV treatment Idvynso provided partial offset.

Over 45 companies are developing 50+ follicular lymphoma therapies, with major pharma players advancing 5+ late-stage candidates using diverse mechanisms including protein degraders and kinase inhibitors.

Global oncolytic virus immunotherapy market projected to exceed $5 billion by 2031, driven by three approved therapies and 150+ clinical candidates advancing combination approaches.

PCPG cancer market projects 7.3% annual growth through 2036, valued at USD 300M in 2025, driven by novel drug classes and Novartis WELIREG leadership.

Novartis offers better dividend yields and diversification than Merck, with stronger long-term prospects despite both beating the S&P 500.

Over 100 pharmaceutical companies compete to develop 120+ NSCLC pipeline drugs, with 30+ in late-stage trials. Precision oncology advances drive innovation in biomarker-selected populations.